Bio-Thera
Solutions, a clinical-stage biopharmaceutical company developing a
pipeline of innovative oncology therapies and a pipeline of biosimilars,
today announced the company will present two posters at the 2019
American Association for Cancer Research ("AACR") Annual Meeting taking
place March 29 - April 3, 2018 in Atlanta, Georgia.
The first
poster, entitled “BAT8001, a potent anti-HER2 antibody drug conjugate
with a novel uncleavable linker to reduce toxicity for patients with
HER2-positive tumor,” will highlight Phase I clinical data demonstrating
the safety and efficacy of BAT8001 in HER2-positive cancer patients. An
abstract of the presentation will be available on AACR website on the day of the presentation.
Presentation details are as follows:
Session Category: Clinical Trials
Session Title: Phase I Clinical Trials: Part 2
Session Date and Time: Monday, April 1, 2019, 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17
Poster Board Number: 10
Abstract Number: CT053
The
second poster, entitled “Development of a potent Trop-2 antibody-drug
conjugate, BAT8003, for the treatment of Trop-2 positive gastric
tumors,” will present preclinical data that highlight advantages of
BAT8003 as a potential treatment for gastric cancer patients. The IND
for a Phase I clinical trial evaluating the safety and pharmacokinetics
of BAT8003 was approved earlier this year by the China NMPA. Dosing of
the first patient in this Phase I clinical trial is expected to occur
during April 2019. An abstract of the presentation is currently available on AACR website.
Presentation details are as follows:
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeted Therapies
Session Date and Time: Wednesday Apr 3, 2019 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 14
Poster Board Number: 9
Abstract Number: 4821
Copies of both posters will be made available on the Company's website after they are presented.
About BAT8001
BAT8001
is an investigational HER2-ADC being evaluated in multiple tumor types.
HER2 is a naturally occurring receptor that is overexpressed in many
types of cancer, including breast cancer and gastric cancer. BAT8001 is
being developed for use as a single agent and in combination with other
agents for the treatment of multiple cancers. BAT8001 is currently
being evaluated as a single agent in a Phase III metastatic breast
cancer trial and in combination with an anti-PD1 antibody in gastric
cancer. Both clinical studies are being run in China.
About BAT8003
BAT8003
is an investigational Trop2-ADC being evaluated in multiple tumor types.
Trop-2 is a naturally occurring receptor that is overexpressed in many
types of cancer, including triple negative breast cancer and gastric
cancer. BAT8003 utilizes Bio-Thera Solutions’ proprietary
linker-payload combination, Batansine. The antibody component of
BAT8003 is engineered for site-specific conjugation to allow for better
control of the ADC DAR, providing a more homogenous product. The linker
is non-cleavable ensuring superior delivery of the payload to the
cancer cells and improving the safety profile of the ADC. BAT8003 is
being developed for use as a single agent and in combination with other
agents for the treatment of Trop2 positive cancers. A Phase I clinical
trial evaluating the pharmacodynamics and safety of BAT8003 will begin
dosing patients during April 2019.